Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nature
Asıl Yazarlar: Kreiter, Sebastian, Vormehr, Mathias, van de Roemer, Niels, Diken, Mustafa, Löwer, Martin, Diekmann, Jan, Boegel, Sebastian, Schrörs, Barbara, Vascotto, Fulvia, Castle, John C., Tadmor, Arbel D., Schoenberger, Stephen P., Huber, Christoph, Türeci, Özlem, Sahin, Ugur
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4838069/
https://ncbi.nlm.nih.gov/pubmed/25901682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14426
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller